Replies to post #323743 on Elite Pharmaceuticals Inc (ELTP)
11/17/19 12:46 PM
it is obvious it has not been excessively done.
11/17/19 12:48 PM
So it is that we investors owe Nasrat and Elite a vote of thanks, respect and trust.
11/17/19 12:56 PM
11/17/19 1:05 PM
11/17/19 1:14 PM
11/17/19 1:24 PM
11/17/19 1:32 PM
11/17/19 2:13 PM
11/17/19 6:31 PM
11/17/19 6:41 PM
11/18/19 1:00 AM
A final thought: Based on a strategic decision that totally realigned its product focus (and which cost additional shares to fund), Elite has become a well-diversified generics company. As a generics firm, the focus is on price not differentiation. SOX was an NDA and, thus, differentiated. It was a strategic anomaly and, I believe, a mistaken decision for a generics firm to make. But I forgive them the mistake because they are not attempting to escalate their financial commitment to an opioid product line that has socio-legal-political issues. Moreover, ADFs, while a grand idea, are and remain a costly drug. ICER has put out a report that indicates ADF opioids are overpriced by 40% and it is a major reason they will not gain the traction with the now cautious prescribers who do not believe their patients are at risk of abuse or diversion. Because the cost of ADF opioids is high, abuse threat low, and many of these people are on fixed incomes and sensitive to pricing, healthcare professionals will not easily prescribe ADFs.
11/18/19 1:40 PM
11/18/19 2:53 PM
11/25/19 1:18 PM
12/14/19 11:32 AM
| Volume | |
| Day Range: | |
| Bid Price | |
| Ask Price | |
| Last Trade Time: |